Constructive Biology Limited is a rapidly growing, research-driven biotechnology company specializing in the development of novel protein and peptide therapeutics. Established in 2021, we are headquartered at 27 Old Gloucester Street, London, WC1N 3AX, with SIC codes - 72110 – focused on biotechnology research and development. Our core competency lies in the creation of innovative therapeutic candidates targeting a range of diseases, with a particular emphasis on oncology and immunology. We leverage a proprietary platform technology, developed collaboratively with Prof. Jason Chin FRS, FRGS, and a team of experienced scientists, to accelerate the discovery and optimization of new drug candidates. Currently, Constructive Biology Limited is actively engaged in preclinical research, including cell-based assays, animal studies, and formulation development. We are focused on identifying and validating novel targets for therapeutic intervention. We have secured a significant Series A funding round, representing $58 million, demonstrating our commitment to substantial investment in our research pipeline. We actively pursue international collaborations and partnerships to expand our research capabilities and accelerate the translation of discoveries into clinical applications. Our international presence is currently focused on strategic collaborations and partnerships within Europe and North America.

Constructive Biology Limited is a rapidly growing, research-driven biotechnology company specializing in the development of novel protein and peptide therapeutics. Established in 2021, we are headquartered at 27 Old Gloucester Street, London, WC1N 3AX, with SIC codes - 72110 – focused on biotechnology research and development. Our core competency lies in the creation of innovative therapeutic candidates targeting a range of diseases, with a particular emphasis on oncology and immunology. We leverage a proprietary platform technology, developed collaboratively with Prof. Jason Chin FRS, FRGS, and a team of experienced scientists, to accelerate the discovery and optimization of new drug candidates. Currently, Constructive Biology Limited is actively engaged in preclinical research, including cell-based assays, animal studies, and formulation development. We are focused on identifying and validating novel targets for therapeutic intervention. We have secured a significant Series A funding round, representing $58 million, demonstrating our commitment to substantial investment in our research pipeline. We actively pursue international collaborations and partnerships to expand our research capabilities and accelerate the translation of discoveries into clinical applications. Our international presence is currently focused on strategic collaborations and partnerships within Europe and North America.